FY2025 EPS Estimates for Opus Genetics Cut by HC Wainwright

Opus Genetics, Inc. (NASDAQ:IRD) – Research analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for Opus Genetics in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($1.09) per share for the year, down from their prior forecast of ($1.03). HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Opus Genetics’ FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.52) EPS and FY2028 earnings at ($0.22) EPS.

Opus Genetics (NASDAQ:IRD) last released its quarterly earnings data on Monday, March 31st. The company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.93). The business had revenue of $3.40 million during the quarter, compared to analyst estimates of $11.10 million. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%.

Separately, Jones Trading dropped their target price on Opus Genetics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday.

Opus Genetics Stock Performance

NASDAQ:IRD opened at $0.93 on Thursday. Opus Genetics has a one year low of $0.81 and a one year high of $1.56. The firm has a market capitalization of $29.89 million, a PE ratio of -0.86 and a beta of 0.28. The firm has a 50 day moving average of $1.07.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.